Q2 2026 Ocugen Inc Earnings Call Transcript

Aug 6, 2026 / 12:30 PM GMT

Release Date Price: $1.25 (-2.34%)

Transcript 10-Q8-K

Key Points

Positve

Ocugen Inc (OCGN) received FDA clearance to initiate its Phase 3 registrational trial for OCU410 in geographic atrophy (GA) and was granted Regenerative Medicine Advanced Therapy (RMAT) designation for the program.
The company's cash runway has been extended into 2028 following the closing of a $130 million convertible notes financing, providing support for all three late-stage programs.
Phase 2 data for OCU410 in GA demonstrated a statistically significant 31% reduction in GA lesion growth at the optimal dose, approximately twice the benefit of approved complement inhibitors, with a single injection.
Enrollment in the Phase 3 limelight trial for OCU400 in retinitis pigmentosa (RP) is complete with 140 patients, spanning more than 30 genetic mutations, validating the gene-agnostic platform.
Ocugen Inc (OCGN) has treated more than 325 patients across its pipeline without observing a drug-related serious adverse event, and remains on track to file three BLAs by 2028.
The company signed a binding term sheet with Roots Pharmaceutical for exclusive rights to OCU400 in the Middle East and North Africa (MENA) region, advancing its global commercialization strategy.

Negative

Ocugen Inc (OCGN) reported a net loss of $0.07 per share for the second quarter of 2026, which is wider than the $0.05 loss per share reported in the same period of 2025.
Total operating expenses increased to $17.9 million for the second quarter of 2026, up from $15.2 million in the prior year period, reflecting higher R&D and G&A costs.
The company's cash position of $100.4 million as of June 30, 2026, is relatively low given the need to fund three late-stage programs, potentially requiring additional capital raises.
The BLA submission for OCU400 has been pushed to the first quarter of 2027, tied to topline data, which is later than the previously guided third quarter of 2026 for rolling submission.
Ocugen Inc (OCGN) plans to hold a special meeting in September 2026 to increase authorized shares, which could lead to shareholder dilution if additional equity is raised.
The Phase 3 Armada 3 trial for GA was resized down to 237 subjects from an earlier estimate of 300, which may raise questions about the robustness of the trial design despite the 95% power calculation.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

OCGN.OQ - Ocugen, Inc.
Q2 2026 Ocugen Inc Earnings Call
Aug 06, 2026 / 12:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good morning and welcome to Oygen second quarter 2006 financial resources and business update.

All participants are in Listen all about it.

Following the speaker's commentary, there will be a question-and-answer session.

I will now turn the call over to Chris Clark, Oxygen's head of communications.

You may begin.

Thank you, Alerd, and good morning, everyone.

Joining me on today's call and webcast is Dr.

Shankar Musso-founder, who will provide a business update and an overview of our clinical and operational progress.

Rita Johnson Green, our Chief Financial Officer, is also on the call to provide a financial update for the quarter ended June 30th, 2026.

Avi Gupta,

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.